AI companies are enabling genocide in China
By Michael Chertoff and N. MacDonnell Ulsch,
The Washington Post
| 04. 12. 2021
"Uyghur man" by Evgeni Zotov is
licensed under CC BY-NC-ND 2.0
The Chinese Communist Party’s persecution of the Uyghur people will go down in history as one of the worst human rights tragedies of our time — not just for the abject horror of targeting a population of 11 million for genocide, but also for the advanced technologies that enabled it.
Like most Chinese citizens, the Uyghurs have long been under constant high-tech surveillance that tracks, analyzes and records their every move and scours their personal communications for evidence of dissent. Compounding this culture of surveillance is the evolution of artificial intelligence from a novelty designed to win games of chess against humans into a science now capable of facial recognition and individual profiling. The Uyghurs have lived in China since the 9th century, yet their persecution has been driven by 21st-century technology.
Beijing has vowed to lead the world in AI, and its documented use in the identification and detention of Uyghurs shows that the regime is getting there quickly. The implications of this campaign are dire. A new...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...